AMO acquires OptiMedica for laser cataract surgery

Article

Abbott Medical Optics (AMO) has announced the acquisition of OptiMedica, enabling expansion into the laser cataract surgery market.

Abbott Medical Optics (AMO) has announced the acquisition of OptiMedica, enabling expansion into the laser cataract surgery market.

The company will acquire OptiMedica for $250 million plus additional payments totalling almost $150 million. OptiMedica will allow AMO to access the Catalys Precision Laser System, which is designed to replace some of the technical demanding manual steps in cataract surgery.

The precise, computer-guided femtosecond laser system can be used to perform capsulotomies, phacofragmentation and incisions for ocular surgery. Catalys has receieved the CE Mark in Europe and approval from the FDA.

Murthy Simhambhatia, senior vice president at AMO, commented, “The acquisition of OptiMedica will provide Abbott with an entry point into the rapidly developing laser cataract surgery market. The Catalys laser system provides physicians with a state-of-the-art, computer-guided alternative in treating patients suffering from cataracts.”

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.